Marco Meglio

Preliminary 12-month data from the JEWELFISH study in previously treated patients showed rapid and sustained increases in survival motor neuron protein levels.

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.

Emphasis on prevention of intracranial hemorrhage at an early stage is recommended to mitigate further risks later in a patient’s life, especially in older individuals.

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Effectively addressing vascular risk factors could provide an important avenue for modifying white matter hyperintensity disease burden.

An overwhelming number of patients with relapsing multiple sclerosis may accumulate disability due to underlying progressive disease course independent of relapse activity.

The study confirmed previous study findings that indicated potential severe conditions such as stroke or inflammatory diseases can appear in later stages of COVID-19, including during recovery.

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

Coutinho et al. noted that future studies that feature a larger population will help to better determine recovery rates after endovascular treatment.

Approximately one-fourth of the excess cases of maternal stroke associated with migraine were attributable to hypertensive disorders.

The first study to attempt to directly compare 3 debated treatment strategies to treat medication overuse headache showed the most significant change in monthly headache days by using withdrawal plus preventive treatment.

The Nippon Shinkyaku therapy also showed no treatment-emergent adverse events that required reduction, interruption, or discontinuation of the treatment.

Non-work-related activity impairment was statistically significantly reduced in the galcanezumab group compared to placebo.

Incident impulse control disorder behaviors through the 5-year follow-up period were correlated with dopamine agonist use and depression, but not with age.

Raising glucose levels may prove to be a simple and novel technique for the prevention and treatment of post-dural puncture headache.

Cenobamate may offer a potential treatment option for patients who continue to have seizures despite the use of available treatments.

Topline results from the phase 3 trial of arimoclomol are expected to be announced in the first half of 2021.

The agent’s developer, Argenx, stated that it plans on submitting a biologics license application (BLA) to the FDA by the end of 2020.

Improvements in function may be mediated by an effect of aerobic fitness on deep gray matter brain structures.

A subset group of inebilizumab-treated patients who did not have adjudicated attacks displayed more than a 2-fold increase in serum CSF glial fibrillary acidic protein from baseline, implying GFAP may serve as a biomarker.

Data from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.

The association between black individuals and processing speeds may explain the black-white disparities in dementia risk at older age.

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.